12 minute read
Get ready for the EAU21 Virtual Congress
European Urology Today
Advertisement
Vol. 33 No.2 - March/May 2021
Genital gender affirmation surgery
ESGURS update on penile reconstruction
Mr. Wai Gin (Don) Lee
23
The e-informed patient
Pros and cons of patient’s internet search
Dr. Markos Karavitakis
27
Digital uropathology in times of COVID-19
ESUP update on remote diagnosis, consultation and distant teaching
Prof. Rodolfo Montironi
Get ready for the EAU21 Virtual Congress!
A preview of the hottest topics that will be discussed this summer
As a preview of the EAU21 Scientific Programme, we spoke to seven experts who were involved in abstract selection and developing the plenary and thematic sessions. Get a glimpse of the EAU’s 36th Annual EAU Congress, the event of the year!
Registration will remain open until 12 July, but the discounted early fee is only available until 1 June. See www.eau2021.org for all the available registration fees, the scientific programme and, of course, the latest congress-related news. Cutting-edge Science at Europe’s largest Urology Congress
Join us!
Prof. Jean-Nicolas Cornu (Rouen, FR): Incontinence
“Urinary incontinence is one of the most frequent urological conditions, especially in the elderly population. The impact of population ageing is already seen in urology wards where patients are older and older. During #EAU21 Virtual congress, a specific focus will be made on UI in the elderly, discussing overactive bladder treatments and surgical options. These options include bulking agents, slings, and artificial urinary sphincter. We will also specifically look at drugs: how and when to use them in daily practice.”
“Experts in incontinence will also discuss pragmatic clinical situations in both sexes, e.g. an artificial sphincter dysfunction in an elderly male, and a case of stress urinary incontinence in an elderly female candidate for surgery. Key opinion leaders will also cover the growing legal and regulatory issues in the field of mesh implantation, and focus on the patient’s perspective.”
“Beyond the plenary session, the rest of the EAU21 programme will also cover hot topics related to incontinence. This includes poster and thematic sessions on cutting-edge scientific reports, updated clinical trials results, and presentations on new instruments and devices.”
Associated Plenary Session Plenary Session 2: Optimal management of incontinence in the elderly patient Friday, 9 July (10:30-12:00) Prof. Evangelos Liatsikos (Patras, GR): Stones and endourology
Prof. Marc-Oliver Grimm (Jena, DE): Renal cell cancer “Stones is always an interesting and relevant part “Renal cell cancer (RCC) is evolving rapidly with regard to Cutting-edge Science at Europe’s largest Urology Congress of urology, it represents a big molecular, diagnostic and part of the activities that treatment research and its urologists are doing in their practice. A lot of implementation in clinical practice. The VHL urologists combine the treatment of urological mechanism in RCC is a good example and all its stones with another specialty. Around 40-50% aspects will be discussed to set the scene of this of our practice is stones so it’s always an session. This is a special lecture on behalf of the interesting topic to discuss.” Society of Urologic Oncology (SUO). For the small Associated Plenary Session renal mass, an update will be given on different Plenary Session 4: “At EAU21 we will cover what is new in stone approaches and will help you to make the right Renal cancer: From localised to metastatic management. The track is designed to cover decision.” disease every part, from shockwave lithotripsy to Saturday, 10 July (11:00-12:30) percutaneous nephrolithotripsy (PCNL) and flexible ureteroscopy. We will discuss hot topics like metabolic evaluation, the medical treatment of urinary stones, and suggested dietary modifications. Stone analysis and the basic Prof. Morgan Roupret “The EAU Guidelines provide clear statements Join evaluation of stone patients are of use to us. (Paris, FR): regarding the usage of perioperative systemic We will also see a case discussion on a young boy, in order to address the paediatric side of stone treatment.” Advanced bladder cancer “Scientific efforts of the last therapy in patients with MIBC. Then should we always perform a radical cystectomy after completer response? Our advanced bladder cancer us! decade have yielded several plenary session will host a debate on the topic.” “Of course endourology is closely linked to novel diagnostic and developments in technology. So delegates can therapeutic opportunities for “Immunotherapy has recently brought a paradigm also expect us to cover everything to do with patients suffering from localized muscle-invasive shift on treatment options for several cancers. single-use ureteroscopes, and new bladder cancer (MIBC) and metastatic disease. In bladder cancer, several treatment options are developments in laser technology. These The management of patients with high-risk MIBC currently available on metastatic disease. technologies evolve almost on a year-by-year remains an unmet need. The EAU scientific These outcomes provided the rationale to attempt basis. It’s important that people hear from the committee office came up with a very challenging utilization on an early phase of the disease. experts what is not just new but also what is session for EAU21.” We will be exploring neo-adjuvant immunotherapy.” objectively an improvement and useful in daily practice.” “To date, several definitions have been applied to “And last but not least, molecular markers appears determine which patients are considered at to be a the ‘new kids on the block.’ Many efforts “Finally, we will also look at surgical training high-risk of recurrence after curative intent have been recently made to classify urothelial and how this can be done in times of pandemic. following radical cystectomy (RC). The current carcinoma of the bladder from a molecular point Perhaps virtual training will play a larger role for therapies that have arisen on the bladder cancer of view, which has several implications for our younger colleagues?” BC armamentarium have generated a myriad of treatment choices and prognosis. This is a hot topic options in terms of medical and surgical therapies, at EAU21 and we will see if molecular markers are Associated Plenary Session as well as optimal sequencing strategies. At EAU21 suitable for being used currently in daily practice.” Plenary Session 7: we will be looking at the increasing popularity of Stones: Keeping with tradition or time PET/CT for the staging of advanced bladder cancer, Associated Plenary Session for new concepts? and what is the most appropriate pre- Plenary Session 3: Monday, 12 July (8:00-9:30) interventional staging modality.” Advanced bladder cancer in 2021: Going forward? Saturday, 10 July (11:00-12:30)
Prof. Silke Gillessen (Bellinzona, CH): Advanced PCa
“In larger tumours there has recently been a shift in surgery towards more nephron sparing. A pro and con discussion on this issue will help delegates finetune their clinical practice. In the mRCC setting prospective randomised trials tried to answer the role of nephrectomy in different eras of systemic therapy. The choice can be individualised and is also dependent on new treatment possibilities. Look forward to a mix of pre-recorded lectures by experts and interactive live discussion led by the session chairmen.” metastatic disease after they have primary treatment. It seems that biologically these groups are different and have a different prognosis. Delegates can look forward to learning about “I think every urologist that which patients could benefit from which deals with metastatic PCa will find something of interest at treatments.”www.eau2021.org EAU21, particularly the plenary “In the coming months we’re also expecting new session. It’s a dynamic field and we’ve seen a lot of data on the combination of different treatment new developments in the last five years.” options. We might have started about 40 years ago with hormonal treatment and androgen deprivation “For instance, there are a lot of new treatment therapy alone. But adding chemotherapy or novel options for metastatic, hormone-sensitive PCa. hormonal agents can be beneficial. For instance, We don’t yet know which option is best for which the addition of radiotherapy for patients with patient. We’re learning more and more that this low-volume disease can give an overall survival is not one group of patients, but that there are benefit. We will also soon know the effects of triple differences between patients with, for example, combinations, for instance ADT plus a novel high or low-volume disease, or patients who are hormonal agent, and also docetaxel. Or combining de novo metastatic or patients who relapse with ADT, radiotherapy, abiraterone and docetaxel. Triple
or quadruple combinations give us a lot of potential therapeutic options.”
“Additional topics that we will discuss in the plenary, thematic and abstract sessions include the potential of personalised medicine, and differentiating between patients who will benefit versus those who won’t. Case presentations are a useful way to illustrate this. We will also look at new, more sensitive imaging options and imaging-guided treatment. Delegates can likely also expect analyses from ongoing trials in the ‘late breaking’ session.”
Associated Plenary Session: Plenary Session 5: Treatment for metastatic hormone-sensitive prostate cancer Sunday, 11 July (11:45-13:15)
European Urology Today
Editor-in-Chief Prof. M. Wirth, Dresden (DE)
Section Editors Prof. T.E. Bjerklund Johansen, Oslo (NO) Mr. Ph. Cornford, Liverpool (GB) Prof. O. Hakenberg, Rostock (DE) Dr. D. Karsza, Budapest (HU) Prof. P. Meria, Paris (FR) Dr. G. Ploussard, Toulouse (FR) Prof. J. Rassweiler, Heilbronn (DE) Prof. O. Reich, Munich (DE) Assoc. Prof. F. Sanguedolce, Barcelona (ES) Prof. S. Tekgül, Ankara (TR)
Special Guest Editor Mr. J. Catto, Sheffield (GB)
Founding Editor Prof. F. Debruyne, Nijmegen (NL)
Editorial Team E. De Groot-Rivera, Arnhem (NL) L. Keizer, Arnhem (NL) H. Lurvink, Arnhem (NL) J. Seesing, Arnhem (NL)
EUT Editorial Office PO Box 30016 6803 AA Arnhem The Netherlands T +31 (0)26 389 0680 F +31 (0)26 389 0674 EUT@uroweb.org
Disclaimer
No part of European Urology Today (EUT) may be reproduced without written permission from the Communication Office of the European Association of Urology (EAU). The comments of the reviewers are their own and not necessarily endorsed by the EAU or the Editorial Board. The EAU does not accept liability for the consequences of inaccurate statements or data. Despite of utmost care the EAU and their Communication Office cannot accept responsibility for errors or omissions. Prof. Alberto Breda (Barcelona, ES): Reconstructive surgery – WIP
“Technological improvement has been the engine that has pushed advances in urology over the last decades. The last frontier of the surgical development was the introduction of robot-assisted surgery, which redefined most of the best-known surgical techniques.”
“In 2021 we can state that the robot-assisted approach has become a routine, also for reconstruction surgery. The high dexterity and enhanced vision offered by robot-assisted procedures allows us to explore different techniques of neobladder after radical cystectomy and even to perform a safe and effective kidney transplantation with a minimally invasive approach. This is why the Annual EAU congress will host, for the first time, a dedicated Plenary Session entitled “Reconstructive surgery: Did the robot take over?”.
“The session will be divided in two main topics discussed by world-renowned experts in the field: reconstructive surgery in benign disease and and in oncology. In the first case, uretero-pelvic junction surgery, iatrogenic ureteral injury repair, robotic surgery in pediatric patients and kidney transplantation will be discussed. In the oncological section, a focus on the various intracorporeal neobladder technique will be provided to end with a panel discussion on their functional outcomes in comparison with traditional techniques. The plenary session also features multiple debates with pre-recorded cases and live discussion.” “The importance of the topic also led to the creation of two dedicated thematic sessions. Thematic Session 18 will provide insights of robotic techniques for lymph node dissection during nephroureterectomy, radical nephrectomy with vena cava thrombectomy. Moreover, laparoscopic retroperitoneal partial nephrectomy will be discussed and compared to the robotic technique while the use of a novel robotic platform will be described for radical prostatectomy.”
“The second, ‘Kidney transplantation in 2021’ (Thematic Session 19), will focus on robot-assisted kidney transplantation, orthotopic kidney transplantation and management of special situations such as ureteral complications, transplant in Jehovah’s witnesses and robotic prostatectomy in transplanted patients.
“Finally, we will examine the future: the surgery of 2030 is being covered in a variety of abstract sessions. The introduction of new technologies for robotic surgery is the next step of innovation. This is leading to overcome challenges of outmost importance linked to this field. For example, the preoperative surgical planning is being revolutionized by 3D reconstruction. The use of augmented reality and near-infrared fluorescence and Indocyanine green (ICG) is currently reported in real-time assessment of tissue viability as well as structures identifications to avoid complication and ischemia of the organ or of the anastomosis.”
Associated Plenary Session Plenary Session 6: Reconstructive surgery: Did the robot take over? Sunday, 11 July (11:45-13:15)
For the latest updates on EAU21, please visit the website www.eau2021.org or follow us on Facebook, Twitter, LinkedIn and Instagram.
“The screening and early detection of prostate cancer has of course been a hot topic in urology for many years (EORTC, Stockholm 3). At EAU21, we’re addressing the issue in a “nightmare session” with consultant solicitor Mr. Bertie Leigh.”
“It’s very important to be aware of the advantages and disadvantages of early detection, and the risks associated with it. Unfortunately, in medicine nothing is ever a 100% vs. a 0% recommendation. You always have to balance advantages and disadvantages when considering treatment options or indeed screening for PCa. You have to balance the risk of overdiagnosis and overtreatment, with the risk of underdiagnosis and undertreatment.”
“The plenary session on early detection will highlight details that urologists always have to keep in mind with early detection. In addition to the respective risks of over- and underdiagnosis, we have to be careful when we rely only on imaging, and then miss the disease because we overestimate capacity of the technology.”
“The use of MRI for PCa detection is maturing and more widespread, but quality is still an issue. Not every MRI achieves the necessary quality to be helpful and reliable. There is a quality issue, so we have to work closely with radiologists on a European level.”
“Beyond the plenary and thematic sessions, we received a lot of abstracts on topics that deal with new technology and surgery. Notably, a lot of abstracts looking at PCa recurrence and a post-treatment rise in PSA. Another hot topic is how to best use MRI as a triage test, and how much we can depend on this technology.”
Associated Plenary Session: Plenary Session 1: Nightmare session: PCa early detection Friday, 9 July (10:30-12:00)
Patient Day
Friday, 9 July
11:30 - 12:30 Prostate Cancer 12:30 - 13:30 Bladder Cancer 13:30 - 14:30 Kidney Cancer 14:30 - 15:30 Life after Cancer Treatment 15:30 - 16:30 Functional Urology 16:30 - 17:30 Patient Poster session 17:30 - 17:40 The Top-5 Best Patient Poster Awards 18:00 - 19:00 Roundtable discussion, ‘The Road to Successful Intervention’
Visit eau2021.org for more information.
Follow us:
